PolyPhotonix Information

PolyPhotonix is a biophotonic research and development company that designs, develops and manufactures non-invasive photonic based medical devices. Established in 2009 in the North East of England, the company is focused on light therapy treatments for macular eye disease and has successfully brought its first medical device through clinical trials to market. Noctura 400 is a CE-marked sleep mask that treats diabetic retinopathy and diabetic macular oedema, two of the leading causes of blindness in working-age adults in the UK. Patients wear it at night during normal sleep. It delivers low-level light therapy through closed eyelids, managing the retina’s nocturnal oxygen demand and slowing or reversing disease progression. No injections. No hospital visits. No disruption to daily life. Clinically proven. NHS adopted. Demonstrated improvement or stabilisation in 96% of patients. We work with NHS commissioners, ophthalmology leads, optometrists, and diabetology teams to integrate Noctura 400 into existing care pathways, offering a non-invasive first-line option that reduces pressure on hospital clinics and saves an estimated £3,000 per patient per year versus current injection-based treatments. To find out more, request clinical information, or discuss pathway adoption, get in touch. 📧 enquiries@polyphotonix.com | 🌐 www.noctura.com